Acute effects of zolpidem, triazolam and flunitrazepam on arterial blood gases and control of breathing in severe COPD.
Patients with severe chronic obstructive pulmonary disease (COPD) commonly complain of insomnia, but hypnotic drugs are generally not recommended due to their depressant effect on the respiratory centres. The aim of this study was, therefore, to compare the effects of a single dose of the benzodiazepine hypnotics, triazolam 0.25 mg and flunitrazepam 1 mg, and a new imidazopyridine compound, zolpidem 10 mg, in hypercapnic COPD patients. Twelve stable COPD patients (mean +/- SD arterial oxygen tension (PaO2) 9.3 +/- 0.8 kPa and arterial carbon dioxide tension (PaCO2) 5.9 +/- 1.9 kPa) were included in the study. The following measurements were performed before and 2 h after drug administration: PaO2 and PaCO2, minute ventilation (VE), mouth occlusion pressure (P0.1), rebreathing CO2 tests with ventilatory response to carbon dioxide stimulation (delta VE/delta PACO2) and mouth occlusion pressure response to carbon dioxide stimulation (delta P0.1/delta PACO2). The measurements were performed in a randomized, double-blind fashion, each patient receiving a single dose of each drug on three different days, separated by a one week interval. No difference was noted between control measurements and those taken 2 h after administration of zolpidem in the following parameters: PaCO2, PaCO2, VE, P0.1, delta VE/delta PACO2 and delta P0.1/PACO2. Two hours after administration of triazolam and flunitrazepam, a significant difference was noted in VE for triazolam and for flunitrazepam. After flunitrazepam administration, a significant decrease in PaCO2 (6 +/- 1.8 at baseline versus 7 +/- 0.4 kPa), and delta VE/PACO2 (0.44 +/- 0.20 at baseline versus 0.31 +/- 0.21 l.min-1 x kPa) were observed.(ABSTRACT TRUNCATED AT 250 WORDS)
Murciano
D
D
Clinique Pneumologique, INSERM U 226, Hôpital Beaujon Clichy, France.
Armengaud
M H
MH
Cramer
P H
PH
Neveux
E
E
L'Héritier
C
C
Pariente
R
R
Aubier
M
M
D001784:Blood Gas Analysis; D002245:Carbon Dioxide / Q000097:blood; D005445:Flunitrazepam / Q000494:pharmacology; D006801:Humans; D006993:Hypnotics and Sedatives / Q000494:pharmacology*; D008173:Lung Diseases, Obstructive / Q000097:blood / Q000503:physiopathology*; D008875:Middle Aged; D010100:Oxygen / Q000097:blood; D011725:Pyridines / Q000494:pharmacology*; D012119:Respiration / Q000187:drug effects*; D014229:Triazolam / Q000494:pharmacology; D000077334:Zolpidem
D006993:Hypnotics and Sedatives; D011725:Pyridines; D002245:Carbon Dioxide; D014229:Triazolam; D005445:Flunitrazepam; D000077334:Zolpidem; D010100:Oxygen